فالنتينا أمبروزيني
Ambrosini, Valentina
VIAF ID: 5943147270518435700003 ( Personal )
Permalink: http://viaf.org/viaf/5943147270518435700003
Preferred Forms
-
100 1 _
‡a
Ambrosini, Valentina
-
100 1 _ ‡a Ambrosini, Valentina
-
100 1 _ ‡a Ambrosini, Valentina
-
100 0 _
‡a
فالنتينا أمبروزيني
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. |
|
| 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. |
|
| 18F-FDG PET/CT detects systemic involvement in sarcoidosis |
|
| ¹⁸F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. |
|
| 18F-FDG PET/CT impact on testicular tumours clinical management. |
|
| 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma |
|
| 68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. |
|
| 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. |
|
| 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. |
|
| 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. |
|
| 68Ga DOTANOC PET/CT detects primary malignant insulinoma. |
|
| ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. |
|
| The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. |
|
| Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. |
|
| Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. |
|
| Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). |
|
| Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma |
|
| The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? |
|
| Detection of unknown primary neuroendocrine tumours |
|
| Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. |
|
| Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients |
|
| Dual PET/CT with |
|
| Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. |
|
| Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. |
|
| FDG PET/CT in autoimmune pancreatitis |
|
| FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. |
|
| FDG small animal PET permits early detection of malignant cells in a xenograft murine model. |
|
| Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. |
|
| Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT |
|
| Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? |
|
| Is there an ideal diagnostic algorithm in solitary pulmonary nodules? |
|
| Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. |
|
| Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. |
|
| Molecular imaging of pulmonary nodules. |
|
| A new dimension of FDG-PET interpretation: assessment of tumor biology. |
|
| Performance evaluation of a small animal PET scanner. Spatial resolution characterization using 18F and 11C |
|
| PET/CT imaging in different types of lung cancer: an overview. |
|
| PET/CT in neuroendocrine tumors, 2016: |
|
| PET/CT with 68Gallium-DOTA-peptides in NET: an overview. |
|
| Positron-emission tomography in gynaecologic malignancies. |
|
| Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. |
|
| Radiopeptide imaging and therapy in Europe. |
|
| Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. |
|
| Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. |
|
| Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. |
|
| Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. |
|
| Small animal PET for the evaluation of an animal model of genital infection. |
|
| Small animal PET in oncology: the road from bench to bedside. |
|
| Standardized uptake values of |
|
| The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. |
|
| The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. |
|
| Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. |
|
